Diabetes Drugs Including Actos and Avandia May Increase Risk of Vision Problems

 

A class of drugs including Actos and Avandia used in the treatment of type 2 diabetes may increase the risk of vision loss, according to a new study.

Though they have proven effective in treating aspects of diabetes, Actos and Avandia—which belong to the thiazolidinedione class of drugs—have also been linked to a host of side-effects. Now, the results of a study published in The Archives of Internal Medicine indicate the drugs may increase the risk of developing macular edema, in which swelling in the retina can cause blindness.

The study focused on more than 100,000 individuals with type 2 diabetes over the span of nearly 10 years. Patients who were taking a thiazolidinedione medication were found to face a two to three times greater risk of developing macular edema than those not taking one of the drugs.

While the research did not provide a direct cause-and-effect relationship between the thiazolidinedione class of drugs and retina damage, it did suggest that those taking Actos or Avandia should have their vision checked regularly to address potential problems early.

Avandia has previously been linked with an increased risk for complications including bone fractures and pulmonary hypertension. Actos has been associated with an increased risk for irregular heartbeat, congestive heart failure and bladder cancer.

If you’re a diabetic and you believe you suffered adverse side-effects from Avandia or Actos, please contact PersonalInjury.com for a free case evaluation and to locate an experienced product liability attorney near you.